Literature DB >> 2139986

Interleukin 2 enhancement of veto suppressor cell function in T-cell-depleted bone marrow in vitro and in vivo.

H Nakamura1, R E Gress.   

Abstract

In allogeneic bone marrow transplantation, graft-versus-host disease can be prevented by the removal of T cells from the donor marrow. The risk of marrow graft rejection is however greater for T-cell-depleted marrow than nondepleted marrow. Cells with a specific type of suppressor activity, termed veto cells, which might depress the host rejection response, have been reported to be present in murine marrow. Among the cell populations that are able to mediate veto activity, there are subpopulations that do not express Thy; such subpopulations might therefore persist following T cell depletion. Since interleukin 2 is able to enhance certain activities of non-T-cells, the ability of interleukin 2 to enhance veto activity of T-cell-depleted marrow was investigated in vitro and in vivo. It was found that the incubation of T-cell-depleted marrow with interleukin 2 significantly increased veto activity as assessed by in vitro assays and also enhanced engraftment of MHC-mismatched, T-cell-depleted marrow in vivo.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2139986     DOI: 10.1097/00007890-199005000-00020

Source DB:  PubMed          Journal:  Transplantation        ISSN: 0041-1337            Impact factor:   4.939


  3 in total

1.  The surprising kinetics of the T cell response to live antigenic cells.

Authors:  Aaron J Tyznik; Michael J Bevan
Journal:  J Immunol       Date:  2007-10-15       Impact factor: 5.422

2.  Clonal deletion of postthymic T cells: veto cells kill precursor cytotoxic T lymphocytes.

Authors:  K Hiruma; H Nakamura; P A Henkart; R E Gress
Journal:  J Exp Med       Date:  1992-03-01       Impact factor: 14.307

3.  Donor CD8 cells prevent allogeneic marrow graft rejection in mice: potential implications for marrow transplantation in humans.

Authors:  P J Martin
Journal:  J Exp Med       Date:  1993-08-01       Impact factor: 14.307

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.